JP2003516418A5 - - Google Patents

Download PDF

Info

Publication number
JP2003516418A5
JP2003516418A5 JP2001543579A JP2001543579A JP2003516418A5 JP 2003516418 A5 JP2003516418 A5 JP 2003516418A5 JP 2001543579 A JP2001543579 A JP 2001543579A JP 2001543579 A JP2001543579 A JP 2001543579A JP 2003516418 A5 JP2003516418 A5 JP 2003516418A5
Authority
JP
Japan
Prior art keywords
compound
amino acid
side chain
acid side
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001543579A
Other languages
English (en)
Japanese (ja)
Other versions
JP4824890B2 (ja
JP2003516418A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/033169 external-priority patent/WO2001042282A1/en
Publication of JP2003516418A publication Critical patent/JP2003516418A/ja
Publication of JP2003516418A5 publication Critical patent/JP2003516418A5/ja
Application granted granted Critical
Publication of JP4824890B2 publication Critical patent/JP4824890B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001543579A 1999-12-08 2000-12-06 免疫抑制剤として使用するためのデプシペプチドおよびその同族体 Expired - Fee Related JP4824890B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16973199P 1999-12-08 1999-12-08
US60/169,731 1999-12-08
US19358200P 2000-03-30 2000-03-30
US60/193,582 2000-03-30
PCT/US2000/033169 WO2001042282A1 (en) 1999-12-08 2000-12-06 Depsipeptide and congeners thereof for use as immunosuppressants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011017260A Division JP2011084585A (ja) 1999-12-08 2011-01-28 免疫抑制剤として使用するためのデプシペプチドおよびその同族体

Publications (3)

Publication Number Publication Date
JP2003516418A JP2003516418A (ja) 2003-05-13
JP2003516418A5 true JP2003516418A5 (enExample) 2008-01-31
JP4824890B2 JP4824890B2 (ja) 2011-11-30

Family

ID=26865325

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2001543579A Expired - Fee Related JP4824890B2 (ja) 1999-12-08 2000-12-06 免疫抑制剤として使用するためのデプシペプチドおよびその同族体
JP2011017260A Withdrawn JP2011084585A (ja) 1999-12-08 2011-01-28 免疫抑制剤として使用するためのデプシペプチドおよびその同族体
JP2013043969A Withdrawn JP2013107902A (ja) 1999-12-08 2013-03-06 免疫抑制剤として使用するためのデプシペプチドおよびその同族体
JP2014155914A Withdrawn JP2014205714A (ja) 1999-12-08 2014-07-31 免疫抑制剤として使用するためのデプシペプチドおよびその同族体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011017260A Withdrawn JP2011084585A (ja) 1999-12-08 2011-01-28 免疫抑制剤として使用するためのデプシペプチドおよびその同族体
JP2013043969A Withdrawn JP2013107902A (ja) 1999-12-08 2013-03-06 免疫抑制剤として使用するためのデプシペプチドおよびその同族体
JP2014155914A Withdrawn JP2014205714A (ja) 1999-12-08 2014-07-31 免疫抑制剤として使用するためのデプシペプチドおよびその同族体

Country Status (16)

Country Link
US (2) US6403555B1 (enExample)
EP (3) EP1246839B1 (enExample)
JP (4) JP4824890B2 (enExample)
KR (1) KR20020062956A (enExample)
CN (1) CN1414971A (enExample)
AT (3) ATE269354T1 (enExample)
AU (1) AU762525B2 (enExample)
BR (1) BR0016154A (enExample)
CA (1) CA2393682C (enExample)
DE (3) DE60011678T2 (enExample)
DK (1) DK1438966T3 (enExample)
ES (3) ES2282751T3 (enExample)
HK (1) HK1049849B (enExample)
IL (2) IL149995A0 (enExample)
PT (1) PT1438966E (enExample)
WO (1) WO2001042282A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7396665B2 (en) 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
US6632553B2 (en) * 2001-03-27 2003-10-14 Mti Microfuel Cells, Inc. Methods and apparatuses for managing effluent products in a fuel cell system
RU2298414C2 (ru) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
CA2495354A1 (en) * 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. An agent for inhibiting articular cartilage extracellular matrix degradation
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
CN1871034B (zh) * 2003-07-09 2011-07-06 亨利福特保健系统公司 用新型腺病毒治疗癌症的方法和组合物
DE602004027824D1 (de) * 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
WO2006055621A2 (en) * 2004-11-17 2006-05-26 The University Of Chicago Histone deacetylase inhibitors and methods of use
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2621560A1 (en) * 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
CA2630216A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
EP1976835A2 (en) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US9539303B2 (en) * 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
CA2670223A1 (en) * 2006-11-22 2008-05-29 Karus Therapeutics Limited Depsipeptides and their therapeutic use
GB0623388D0 (en) * 2006-11-23 2007-01-03 Univ Southampton Chemical compounds
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
EP2102230A2 (en) 2006-12-29 2009-09-23 Gloucester Pharmaceuticals, Inc. Purifiction of romidepsin
CN103497238A (zh) 2006-12-29 2014-01-08 细胞基因公司 制备Romidepsin
WO2008151306A1 (en) * 2007-06-05 2008-12-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Synthesis of cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity
GB0715750D0 (en) * 2007-08-13 2007-09-19 Karus Therapeutics Ltd Chemical compounds
WO2009078875A1 (en) * 2007-12-19 2009-06-25 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US20090280169A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
WO2009141658A1 (en) * 2008-05-22 2009-11-26 Karus Therapeutics Limited Depsipeptides and their therapeutic use
WO2009141657A1 (en) * 2008-05-22 2009-11-26 Karus Therapeutics Limited Depsipeptides and their therapeutic use
ES2621849T3 (es) * 2009-06-26 2017-07-05 Sunny Pharmtech Inc. Método de tratamiento o mejora de toxicidades mucocutáneas u oculares.
TWI412359B (zh) * 2009-07-07 2013-10-21 Asan Lab Co Ltd 組織蛋白去乙醯酵素抑制劑在製備治療或減緩黏膜／皮膚或眼睛毒性或副作用之藥物的用途
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
WO2013047509A1 (ja) * 2011-09-30 2013-04-04 国立大学法人東北大学 新規ホスファチジルイノシトール３キナーゼ阻害剤及び医薬組成物
CA2866392C (en) 2012-03-30 2023-10-24 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
TWI702046B (zh) * 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
CN110760564A (zh) * 2019-10-16 2020-02-07 菲诺克生物科技(上海)有限公司 细胞周期检测方法及其所用试剂与试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268516A (en) 1978-10-11 1981-05-19 Pfizer Inc. [1]Benzothiopyrano[4,3-c]pyrazoles as immunoregulatory agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
WO1993019778A1 (en) 1992-04-07 1993-10-14 The Scripps Research Institute Method for inducing tolerance to an antigen using butyrate
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5591717A (en) 1994-04-06 1997-01-07 Rojko; Jennifer L. Branched apogenic peptide for inducing apoptosis
WO1995033823A1 (en) 1994-06-03 1995-12-14 The United States Of America, Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
WO1999014241A2 (en) 1997-09-17 1999-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5843943A (en) 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5962019A (en) 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5891653A (en) 1995-12-29 1999-04-06 Attfield; Derrick Cecil Method of suppressing graft rejection by means of stress proteins
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
CA2283161A1 (en) 1997-03-03 1998-09-11 Duke University Immunosuppression
DE19713626A1 (de) * 1997-04-02 1998-10-08 Bayer Ag Neue Thiodepsipeptide zur Bekämpfung von Endoparasiten und ein einfaches Verfahren zu ihrer Herstellung
WO1998046640A2 (en) 1997-04-15 1998-10-22 Coulter International Corp. Methods and compositions for inducing immunosuppression
NZ503061A (en) 1997-09-02 2001-08-31 Japan Energy Corp Cyclic tetrapeptide derivatives and use as anti-cancer agents
WO1999015174A1 (en) 1997-09-22 1999-04-01 Sloan-Kettering Institute For Cancer Research Reverse prenyl compounds as immunosuppressants
WO1999025703A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Immunosuppressant tetracyclic triterpenes
WO1999030730A1 (en) 1997-12-15 1999-06-24 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
JPH11180873A (ja) 1997-12-22 1999-07-06 Kaken Shoyaku Kk ＮＦ−κＢ活性阻害剤
US6211145B1 (en) * 1997-12-25 2001-04-03 Nisshin Flour Milling Co., Ltd. Bicyclic depsipeptides
US6001815A (en) * 1997-12-25 1999-12-14 Nisshin Flour Milling Co., Ltd. Depsipeptides containing N-substituted glycine residue
EP0931792B1 (en) * 1998-01-27 2004-01-07 Nisshin Seifun Group Inc. Depsipeptides containing non-natural amino acids
US6287843B1 (en) 1998-04-03 2001-09-11 Pioneer Hi-Bred International, Inc. Maize histone deacetylases and their use
DK1142905T3 (da) * 1999-01-13 2006-09-18 Astellas Pharma Inc Hidtil ukendt depsipeptidforbindelse

Similar Documents

Publication Publication Date Title
KR101178318B1 (ko) 효과적인 의약의 사용법 및 부작용 발현의 방어에 관한방법
JP3226545B2 (ja) ラパマイシン誘導体
WO2006017853A3 (en) Mutant interleukin-15-containing compositions and suppression of an immune response
Cobbold et al. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance
JP2011529918A5 (enExample)
JP2002505292A5 (enExample)
JP2021536237A5 (enExample)
CA2189830A1 (en) Uses for Corticotropin Releasing Factor Atagonists
CA2468552A1 (en) 3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
JP2005502716A5 (enExample)
CA2441410A1 (en) Compounds and method of treatment having agonist-like activity selective at alpha 2b or 2b/2c adrenergic receptors
JP2002516817A5 (enExample)
RU2010109542A (ru) Производные пиридина в качестве модуляторов s1p1/edg1 рецептора
JP2002512989A5 (enExample)
EP1125936A3 (en) Aryl substituted azabenzimidazoles and their use in the treatment of HIV and AIDS related diseases
IL239119A (en) Diazole for Cuttings
JP2011519360A5 (enExample)
JP2005502636A5 (enExample)
BE1003632A3 (fr) Nouveaux derives de l'adenosine, leur preparation et leur utilisation comme medicaments.
WO2008018447A1 (en) Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
CA2452920A1 (en) Benzo [g] quinoline derivatives for treating glaucoma and myopia
JP2002097158A5 (enExample)
JP2004529091A5 (enExample)
Sosman et al. The graft-vs.-leukemia effect: Implications for post-marrow transplant antileukemia treatment
JP2003532737A5 (enExample)